European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia Read more about European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab) Read more about Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)
EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture Read more about EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price Read more about Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference Read more about Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference
Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim) Read more about Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)
Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology Read more about Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners Read more about Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration Read more about Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia Read more about FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
